NRBO - NeuroBo Pharmaceuticals Inc Debt to Book Capitalization Ratio

Corporate company logo of NeuroBo Pharmaceuticals (NRBO)

The correlation of financial liabilities to book capitalization for NeuroBo Pharmaceuticals (NRBO) on the GURU.Markets line chart contains data on drug production via contractors, where 0.02 defines the current value of the indicator. This price action reflects trials of MASH and obesity treatments supported by Dong-A ST. The strategy is based on the development of small molecules to expand within the weight-loss drug market.

NeuroBo Pharmaceuticals (NRBO) - Debts to Book Value from 07/04/2022 to 12/07/2024
Flagship merchandise of NeuroBo Pharma

Financial stability prior to the drug commercialization stage is critical for NeuroBo Pharmaceuticals (NRBO) within the biopharmaceutical sector. This metric compares total liabilities to equity, determining the company's degree of reliance on external financing. By analyzing the debt-to-equity ratio of the company, an investor assesses default risk and leverage levels. The partnership with Dong-A ST optimizes R&D expenses, maintaining a healthy balance sheet structure. A decrease in this ratio confirms high business autonomy and the preservation of investments.

Who NeuroBo Pharmaceuticals competes with

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|XENE (Xenon Corp) - Debts to Book Value|Debt to Book Capitalization Ratio Viking Therapeutics (VKTX)|Debt to Book Value Ratio supernus.com|Catalyst Pharmaceuticals, Inc. - Debts to Book Capitalization|Debts to Book Value Denali DNLI|Debt to Book Value HRMY (Harmony Pharma)|Biohaven Corp - Debts to Book Capitalization|Debt to Book Capitalization Ratio Amylyx Pharmaceuticals (AMLX)|TRVI: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio PRAX|Anavex (AVXL) - Debts to Book Value|Debts to Book Capitalization CeriBell Corp|Debt to Book Capitalization Ratio PRTA|Alector, Inc. - Debt to Book Capitalization Ratio|Debts to Book Value annexonbio.com ANNX|Debt to Book Value Omeros|Neurogene Inc - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio AC Immune Corp|VYGR - Debts to Book Capitalization Ratio|Debts to Book Capitalization Neumora Therapeutics NMRA|scilexholding.com (SCLX) - Debt to Net Assets Ratio|TVGN (Tevogen Bio) - Debts to Book Capitalization|Debts to Book Capitalization ACOG|Cognition Therapeutics (CGTX) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio IKT (Inhibikase Pharma)|Cassava Sciences, Inc. - Debt to Book Capitalization Ratio|Debt to Book Value Assertio Holdings ASRT|Coya - Debts to Book Capitalization|VTGN - Debts to Book Capitalization|OVID (ovidrx.com) - Debts to Book Capitalization|Acumen Pharmaceuticals, Inc (ABOS) - Debt to Book Value|Debts to Book Capitalization CRVO (CervoMed Inc.)|Debts to Book Value Alterity Therapeutics Ltd (ATHE)|Debt to Book Value CLNN|Debts to Book Capitalization pepgen.com PEPG|Debt to Book Value Jupiter Neurosciences Inc (JUNS)|Debt to Book Capital Relmada Corp RLMD|Debts to Book Capitalization ANVS (Annovis Bio, Inc.)|GRCE - Debts to Net Assets|AIFF (Firefly Neuroscience) - Debts to Book Capitalization|Klotho Neurosciences (KLTO) - Debt to Book Value|NRSN (NeuroSense Therapeutics Ltd) - Debts to Book Capitalization|Debts to Book Capitalization RVPH|Debt to Book Capitalization Ratio MetaVia Inc (MTVA)|Debt to Book Capitalization Ratio NRXS (neuraxis.com)|Debt to Book Capitalization Ratio HSDT|Passage Bio Inc. - Debts to Net Assets|Neuphoria (NEUP) - Debt to Book Capitalization Ratio|NERV: Debt to Book Value Ratio|Debt to Book Capitalization Ratio Athira Pharma, Inc. ATHA|addextherapeutics.com (ADXN) - Debt to Net Assets Ratio|Debts to Book Capitalization Alzamend Neuro Inc.|Debt to Book Capitalization Ratio CYCN|Protagenic Therapeutics - Debt to Book Capitalization Ratio|Debts to Book Value KTTA (pasitheaclinics.com)|CRGT - Debt to Book Capitalization Ratio|Debt to Book Value Ratio avenuetx.com ATXI|BCLI (BrainStorm Cell Therapeutics) - Debts to Book Capitalization|Cara Therapeutics Inc. (CARA) - Debts to Book Value|CHRO: Debt to Book Value|ELYM (Eliem Therapeutics Inc.) - Debts to Book Capitalization|ITCI - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio LBPH|Marinus Pharmaceuticals, Inc. - Debt to Book Capitalization Ratio|Debts to Book Value NKGN (NKGen Biotech Inc)|SAGE - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Synaptogenix, Inc SNPX|TRVN (Trevena, Inc.) - Debts to Book Capitalization|Vigil Neuroscience (VIGL) - Debts to Book Value|WENA: Debt to Book Value|CERE (Cerevel Therapeutics Inc) - Debts to Book Capitalization